ValuEngine Downgrades Catalent (CTLT) to Hold

Catalent (NYSE:CTLT) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a report issued on Tuesday.

CTLT has been the topic of several other research reports. UBS Group began coverage on Catalent in a research note on Tuesday, October 9th. They issued a “neutral” rating and a $48.00 price target on the stock. JPMorgan Chase & Co. lifted their price target on Catalent from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Wednesday, August 29th. Finally, Zacks Investment Research raised Catalent from a “sell” rating to a “hold” rating in a research note on Tuesday, October 30th. Six analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Catalent presently has a consensus rating of “Buy” and an average price target of $49.33.

CTLT stock traded down $5.33 during midday trading on Tuesday, hitting $36.11. 2,533,135 shares of the company’s stock were exchanged, compared to its average volume of 929,660. Catalent has a one year low of $34.24 and a one year high of $47.87. The firm has a market cap of $6.11 billion, a PE ratio of 22.71, a P/E/G ratio of 2.50 and a beta of 1.45. The company has a current ratio of 2.15, a quick ratio of 1.79 and a debt-to-equity ratio of 2.44.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Tuesday, November 6th. The company reported $0.28 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.28. Catalent had a return on equity of 20.42% and a net margin of 3.39%. The firm had revenue of $551.80 million for the quarter, compared to the consensus estimate of $582.44 million. During the same quarter last year, the business posted $0.21 EPS. The company’s revenue for the quarter was up 1.5% on a year-over-year basis. On average, analysts forecast that Catalent will post 1.72 earnings per share for the current year.

In related news, SVP Lance Miyamoto sold 6,525 shares of Catalent stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $42.50, for a total value of $277,312.50. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Barry Littlejohns sold 47,265 shares of Catalent stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $41.64, for a total value of $1,968,114.60. The disclosure for this sale can be found here. Insiders sold a total of 184,335 shares of company stock worth $8,161,727 in the last three months. Company insiders own 1.40% of the company’s stock.

Several large investors have recently added to or reduced their stakes in CTLT. Millennium Management LLC increased its position in shares of Catalent by 4,244.2% in the second quarter. Millennium Management LLC now owns 1,200,267 shares of the company’s stock valued at $50,279,000 after acquiring an additional 1,172,638 shares during the last quarter. Redmile Group LLC acquired a new stake in shares of Catalent in the second quarter valued at about $27,725,000. Macquarie Group Ltd. increased its position in shares of Catalent by 25.2% in the second quarter. Macquarie Group Ltd. now owns 2,349,059 shares of the company’s stock valued at $98,402,000 after acquiring an additional 472,228 shares during the last quarter. Paloma Partners Management Co acquired a new stake in shares of Catalent in the second quarter valued at about $16,387,000. Finally, First Trust Advisors LP grew its holdings in Catalent by 443.5% during the third quarter. First Trust Advisors LP now owns 435,632 shares of the company’s stock worth $19,843,000 after purchasing an additional 355,480 shares during the period. 92.08% of the stock is currently owned by institutional investors and hedge funds.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

See Also: What is Liquidity?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply